Sio Gene Therapies’ Exit From Oxford Biomedica Parkinson’s Collaboration Leaves Hole In Commercial Prospects

Firm Loses CEO

 
• By Ayisha Sharma

Sio Gene Therapies is returning its rights for a Parkinson’s disease program to Oxford Biomedica, leaving observers regretting the loss of a big market opportunity, while the US firms seeks a new CEO.    

Parkinson's disease, substantia nigra, Lewy bodies.
Parkinson's Disease Represented The Biggest Market Opportunity For The Firm, One Expert Said. • Source: Alamy

More from Business

More from Scrip